pre-tx 18 f-fdopa pet pre-tx t1+c post-tx 18 f-fdopa pet difference post-pre tx 18 f-fdopa pet iois:...
TRANSCRIPT
Pre-Tx 18F-FDOPA PET
Pre-Tx T1+C
Post-Tx 18F-FDOPA PET
Difference Post-Pre Tx 18F-FDOPA PET
IOIS: 3401
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM)
RESPONDER Change in 18F-FDOPA Signal
+ Increase- Decrease
Pre-Tx T1+C
Difference Post-Pre Tx 18F-FDOPA PET
IOIS: 3401
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM)
Change in 18F-FDOPA Signal
+ Increase- Decrease
Pre-Tx 18F-FDOPA PET
Pre-Tx T1+C
Post-Tx 18F-FDOPA PET
Difference Post-Pre Tx 18F-FDOPA PET
IOIS: 2383
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM)
NON-RESPONDER Change in 18F-FDOPA Signal
+ Increase- Decrease
Pre-Tx T1+C
Difference Post-Pre Tx 18F-FDOPA PET
IOIS: 2383
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM)
NON-RESPONDER Change in 18F-FDOPA Signal
+ Increase- Decrease
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM)
NON-RESPONDER
Change in 18F-FDOPA Signal
+ Increase- Decrease
RESPONDERPre-Tx DOPA Tumor Volume = 117.5 mL
DOPA PRM
% Decreasing DOPA Uptake = 93.0%% Increasing DOPA Uptake = 7.0 %
Pre-Tx DOPA Tumor Volume = 18.3 mL
DOPA PRM
% Decreasing DOPA Uptake 72.8%% Increasing DOPA Uptake = 27.2 %
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM)
% Change in 18F-FDOPA Signal
+ 100%- 100%
RESPONDER
> 50% Change
% Decreasing DOPA Uptake = 93.0%% Decreasing > 25% change = 47.9%% Decreasing > 50% change = 18.2%
% Increasing DOPA Uptake = 7.0 %% Increasing > 25% change = 0.9%% Increasing > 50% change = 0.0%
> 25% Change
All Changes
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM)
% Change in 18F-FDOPA Signal
+ 100%- 100%
NON-RESPONDER
> 50% Change
% Decreasing DOPA Uptake = 72.8%% Decreasing > 25% change = 31.9%% Decreasing > 50% change = 2.7%
% Increasing DOPA Uptake = 27.2 %% Increasing > 25% change = 3.2%% Increasing > 50% change = 0.05%
> 25% Change
All Changes
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM)
% Decreasing DOPA % Increasing DOPA
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM)
NON-RESPONDER
Change in 18F-FDOPA Signal
+ Increase- Decrease
RESPONDER
VOLUME OF DECREASING DOPA UPTAKE = 7.4 mLVOLUME OF INCREASING DOPA UPTAKE = 1.2 mL
VOLUME OF DECREASING DOPA UPTAKE = 175.5 mLVOLUME OF INCREASING DOPA UPTAKE = 0.8 mL
XXXX18F-FDOPA PET Parametric Response Maps (PET PRMs)
Change in PET Signal
-5000 + 5000Baseline: 3/10/09
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
10/20/09
3/30/10
10/12/10
2/15/11
XXXX18F-FDOPA PET Parametric Response Maps (PET PRMs)
Baseline: 3/10/09
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
Pre-Tx 18F-FDOPA PET
Pre-Tx T1+C
Pre-Tx 18F-FLT PET
Combined 18F-FLT and 18F-FDOPA
FLT DOPA FLT+DOPA
IOIS: 3401
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
MALIGNANT MARKER MAPS (18F-FLT and 18F-FDOPA )
Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011
MALIGNANT MARKER MAPS (18F-FDOPA + CBV + ADC )